NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
William G. Wierda, Jennifer R. Brown, Jeremy S. Abramson, Farrukh T. Awan, S Bilgrami, Greg Bociek, Danielle M. Brander, Asher Chanan‐Khan, Steven Coutré, Randall S. Davis, Herbert Eradat, Christopher D.�M. Fletcher, Sameh Gaballa, Armin Ghobadi, Muhammad Saad Hamid, Francisco J. Hernandez‐Ilizaliturri, Brian T. Hill, Paul Kaesberg, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Anthony Mato, Claudio A. Mosse, Stephen J. Schuster, Tanya Siddiqi, Deborah M. Stephens, Chaitra S. Ujjani, Nina D. Wagner‐Johnston, Jennifer A. Woyach, J Christine Ye, Mary A. Dwyer, Hema Sundar
Abstract
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.